<DOC>
	<DOCNO>NCT02571049</DOCNO>
	<brief_summary>Pilot study compare efficacy safety two strengths injection subcutaneous DFN-11 subject rapidly escalate migraine headache .</brief_summary>
	<brief_title>Pilot Study Two Different Strengths DFN-11 Injection Rapidly Escalating Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . Diagnosis episodic migraine , without aura least 1 year prior screen 2 . Experience average 2 8 migraine per month past 12 month approximately 75 % rapidly escalate moderate severe pain within 2 hour onset 3 . Females must : practice effective method birth control ( e.g . prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , doublebarrier method [ e.g. , condom , diaphragm , cervical cap spermicidal foam , cream , gel ] , male partner sterilization ) entry throughout study , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , postmenopausal ( spontaneous amenorrhea least 1 year ) 4 . Females childbearing potential must negative urine pregnancy test screen 5 . Able willing read comprehend write instruction complete electronic diary information require protocol 6 . Must internet access complete daily headache diary 1 . Inability distinguish migraine primary headache 2 . Experiences headache kind frequency great equal 15 day per month 3 . Chronic opioid therapy ( &gt; 10 day 30 day prior screen ) 4 . Current treatment monoamine oxidase A ( MAOA ) inhibitor use within 4 week randomization 5 . Hemiplegic basilar migraine 6 . History , symptom sign ischemic cardiac , cerebrovascular peripheral vascular syndrome 7 . Uncontrolled hypertension ( screen systolic/diastolic blood pressure &gt; 140/90 mmHg 2 3 reading ) 8 . History epilepsy condition associate , opinion Investigator , increase likelihood present day seizure 9 . History ( within 2 year ) drug alcohol abuse define DSMIVTR criterion . 10 . Systemic disease , opinion Investigator , would contraindicate participation 11 . History neurological psychiatric condition , opinion Investigator would contraindicate participation 12 . Pregnant lactate woman 13 . Have take investigational medication within 30 day randomization , schedule receive investigational drug 14 . Subjects positive urine drug screen recreational drug marijuana ( whether legal ) prescription drug explain state concomitant medication 15 . Clinical laboratory electrocardiogram ( ECG ) abnormality opinion Investigator would endanger subject interfere study conduct . If result clinical laboratory ECG outside normal reference range subject may still enrol finding determine clinically significant Investigator . This determination must record subject 's source document prior enrolment . 16 . Fridericia 's correct QT ( QTcF ) interval great 450 msec 17 . Severe renal impairment ( creatinine &gt; 2 mg/dl ) 18 . Serum total bilirubin &gt; 2.0 mg/dL 19 . Serum aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase &gt; 2.5 time upper limit normal 20 . Subjects opinion investigator experience rebound headache caffeine usage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>